Clinical trials: sponsored by Peking University
Melanoma
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced melanoma patients by using a…
- Trial name
- NCT02671513
- Testing
- SHR6390
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastric Cancer.
The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.
Evaluate the feasibility ,safety and efficacy of Surgery，Chemotherapy in Combination with Autologous T cells-Based Immunotherapy for Advanced Gastric Cancer.
- Trial name
- NCT02704299
- Testing
- Autologous T cells-Based Immunotherapy
- Volunteers
- 36 people
- Sponsor
- Shanghai AbelZeta Ltd.
Health Behavior
Short and Long Term Effect of Early Infant Feeding and Nutritional Status on the Children's Health
This study evaluates the early infant feeding in the infant intestinal microecology and the long term health. 300 healthy term newborns were involved into the study on its first stage.
- Trial name
- NCT02658500
- Testing
- Infant Formula, breast milk
- Where
- 4 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beijing Sanyuan Foods Co Ltd
Colorectal Cancer, Adenomatous Polyp of Colon
CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population
The purpose of this study is to evaluate the performance of the SEPT9 gene methylation assay in Colorectal cancer (CRC) high-risk population in Chinese hospitals using the opportunistic screening method.
- Conditions
- Colorectal Cancer, Adenomatous Polyp of Colon, Polyps, Other Disease/Injury
- Trial name
- RESEPT (NCT02540850)
- Where
- 4 sites in China
- Volunteers
- 1,031 people, healthy volunteers welcome
- Sponsor
- BioChain (Beijing) Science and Technology, Inc.
Neutropenia
Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
This study will assess the Efficacy and Safety of different doses of PEG-rhG-CSF and a single-dose of G-CSF in Preventing Chemotherapy-induced Neutropenia.
- Trial name
- PEG-rhG-CSF (NCT01918241)
- Testing
- pegfilgrastim,30mcg/kg, pegfilgrastim, 60mcg/kg, pegfilgrastim, 100mcg/kg
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Chronic Hepatitis B
Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
This study is aimed to assess the efficacy and safety of Peginterferon alfa-2b (40kD, Y-shape), in a dose of 180μg/week, in chronic hepatitis B patients, and collects sufficient evidences for the listed of the studied drug.
- Trial name
- NCT01760122
- Testing
- Ypeginterferon alfa-2b, Pegasys
- Where
- 43 sites in China
- Volunteers
- 820 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Underdose (Unintentional), Cancer
Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia
Safety and efficacy studies of rHSA/GCSF fusion protein for injection in treatment of neutropenia induced by chemotherapy of cancer patients.
- Conditions
- Underdose (Unintentional), Cancer, Tumor
- Trial name
- NCT01919710
- Testing
- rHSA/GCSF
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Anovulation
Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation
The purpose of this study is to evaluate the efficacy and safety of Domestic Recombinant Human Follitropin (Gonal-F) for Injection for treatment of WHO Ⅱ anovulation (including polycystic ovarian syndrome [PCOS] subjects).
- Trial name
- NCT02335879
- Testing
- Gonal-F
- Volunteers
- 534 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Hyperlipidemia
Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
The purpose of this study is to demonstrate the efficacy of XueZhiKang to improve plasma lipid profile, as compared to placebo, in outpatients with hyperlipidemia.
- Trial name
- NCT01327014
- Testing
- XueZhiKang (XZK), a botanic product with multiple components
- Where
- 13 sites in United States, China
- Volunteers
- 116 people
- Sponsor
- Beijing Peking University WBL Biotech Co., Ltd.
Coronary Artery Disease
A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment
research topic:helios After registration of clinical research bidders:kinhely bio-tech Co.Ltd study design:A prospective single treatment group multicenter clinical study Number of patients:Included in the subjects of 800 cases…
- Trial name
- Pro-HOPE (NCT01880879)
- Testing
- helios stent
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Kinhely Bio-tech Co., Ltd.
Essential Hypertension
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.
- Trial name
- NCT01848873
- Testing
- Amlodipine, amlodipine-FA tablet, low dose group, amlodipine-FA tablet ,high dose group
- Where
- 16 sites in China
- Volunteers
- 756 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Chronic Hepatitis C
Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C
This study is a multi-center, randomized, open-label and positive controlled Phase II Clinical trial to assess the efficacy and safety of Ypeginterferon alfa-2b (with Ribavirin), once a week, in 3 dose-groups respectively, for…
- Trial name
- PEGIFN (NCT01140997)
- Testing
- Ypeginterferon alfa-2b, Peginterferon alfa-2a
- Where
- 38 sites in China
- Volunteers
- 211 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Anemia in End Stage Renal Disease
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease (ESRD) on maintenance hemodialysis and receiving epoetin…
- Trial name
- NCT01596855
- Testing
- FG-4592, Epoetin Alfa
- Where
- 9 sites in China
- Volunteers
- 96 people
- Sponsor
- Kyntra Bio
Chronic Hepatitis B
Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
This study is a multi-center, randomized, open-label and positive controlled Phase II Clinical trial to assess efficacy and safety of Ypeginterferon alfa-2b, once a week, in 3 dose-groups: 90mcg, 135mcg and 180mcg, respectively…
- Trial name
- NCT01143662
- Testing
- Ypeginterferon alfa-2b, Peginterferon alfa-2a
- Where
- 39 sites in China
- Volunteers
- 205 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Plasma Cell Leukemia, Multiple Myeloma
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Bortezomib/Liposomal doxorubicin (V-DD) is preferred to bortezomib single agent in salvage therapy for Multiple Myeloma (MM). The present study is designed to assessment the efficacy and safety study of Bortezomib in combination…
- Trial name
- Bortezomib (NCT01328236)
- Testing
- Bortezomib, Liposome doxorubicin, Dexamethasone
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Clinical Service, China
Non-small Cell Lung Cancer
Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.
- Trial name
- NCT01391260
- Testing
- Gefitinib
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- ZhuGuangYing
Type 2 Diabetes
The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
This research is randomized, controlled trial. 36 Chinese subjects with Type 2 Diabetes Mellitus will take part in the trial. Subjects will randomly enter into one of three groups, administration daily twice, the period of is 84…
- Trial name
- SPPS (NCT01342042)
- Testing
- rExenatide-4
- Where
- China
- Volunteers
- 36 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.